Traders sold shares of Pfizer, Inc. (NYSE:PFE) on strength during trading hours on Tuesday. $63.91 million flowed into the stock on the tick-up and $108.69 million flowed out of the stock on the tick-down, for a money net flow of $44.78 million out of the stock. Of all stocks tracked, Pfizer had the 0th highest net out-flow for the day. Pfizer traded up $0.39 for the day and closed at $33.15

Several equities analysts recently commented on PFE shares. Cowen and Company set a $43.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Monday, July 10th. Barclays PLC restated a “buy” rating and set a $38.00 target price on shares of Pfizer in a research report on Wednesday, May 3rd. Sanford C. Bernstein reaffirmed a “buy” rating and set a $37.00 price target on shares of Pfizer in a report on Wednesday, May 3rd. UBS AG reaffirmed a “buy” rating and set a $38.00 price target on shares of Pfizer in a report on Monday, July 31st. Finally, Jefferies Group LLC reaffirmed a “hold” rating and set a $35.00 price target (up from $34.00) on shares of Pfizer in a report on Friday, July 14th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $37.61.

The company has a 50 day moving average price of $33.26 and a 200 day moving average price of $33.41. The company has a market capitalization of $197.69 billion, a price-to-earnings ratio of 24.32 and a beta of 1.00.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.64 earnings per share. Equities analysts anticipate that Pfizer, Inc. will post $2.56 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 3.85%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s dividend payout ratio (DPR) is 94.12%.

In related news, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the transaction, the insider now owns 151,474 shares in the company, valued at $5,074,379. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Ian C. Read sold 96,950 shares of the business’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 120,014 shares of company stock valued at $4,062,493. Insiders own 0.06% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Farmers National Bank boosted its position in shares of Pfizer by 3.2% in the second quarter. Farmers National Bank now owns 107,106 shares of the biopharmaceutical company’s stock valued at $3,598,000 after buying an additional 3,352 shares in the last quarter. RNC Capital Management LLC boosted its position in shares of Pfizer by 3.7% in the second quarter. RNC Capital Management LLC now owns 1,080,976 shares of the biopharmaceutical company’s stock valued at $36,310,000 after buying an additional 38,619 shares in the last quarter. Sentry Investment Management LLC boosted its position in shares of Pfizer by 1.0% in the second quarter. Sentry Investment Management LLC now owns 478,557 shares of the biopharmaceutical company’s stock valued at $16,075,000 after buying an additional 4,775 shares in the last quarter. Atlantic Trust LLC boosted its position in shares of Pfizer by 19.8% in the second quarter. Atlantic Trust LLC now owns 27,400 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 4,530 shares in the last quarter. Finally, WFG Advisors LP boosted its position in shares of Pfizer by 14.5% in the second quarter. WFG Advisors LP now owns 55,528 shares of the biopharmaceutical company’s stock valued at $1,865,000 after buying an additional 7,024 shares in the last quarter. Institutional investors own 69.94% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.dailypolitical.com/2017/08/24/traders-sell-pfizer-inc-pfe-on-strength-pfe-6.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.